Literature DB >> 498704

Sulfinpyrazone kinetics after intravenous and oral administration.

J B Lecaillon, C Souppart, J P Schoeller, G Humbert, P Massias.   

Abstract

Sulfinpyrazone kinetics has been investigated after intravenous and oral doses. They may be described by a 3-compartment open model. In the body about half the drug is in the plasma or in interstitial fluids, which equilibrated with plasma. Most of the rest is in an extravascular compartment, from which it easily diffuses back to the plasma. About 3% of the dose is still in the body after 24 hr and is located mainly in a deep compartment. After oral administration, sulfinpyrazone is quickly absorbed, largely from the stomach.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498704     DOI: 10.1002/cpt1979265611

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

2.  Renal clearance of sulphinpyrazone in man.

Authors:  E G Lentjes; F G Russel; C A van Ginneken
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Sulphinpyrazone increases lymphocyte beta-adrenoceptors in man.

Authors:  A De Blasi; S Cotecchia
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

4.  Plasma levels and pharmacokinetics of sulphinpyrazone in renal impairment during chronic treatment: a case report.

Authors:  J Godbillon; J P Schoeller; S Gauron; G Gosset; J P Fillastre
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

5.  Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.

Authors:  B Rosenkranz; C Fischer; P Jakobsen; A Kirstein Pedersen; J C Frölich
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.

Authors:  A K Pedersen; P Jakobsen; J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Sulphinpyrazone metabolism during long-term therapy.

Authors:  A K Pedersen; P Jakobsen
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

8.  Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.

Authors:  I D Bradbrook; V A John; P J Morrison; H J Rogers; R G Spector
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

Review 9.  Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.

Authors:  E H Margulies; A M White; S Sherry
Journal:  Drugs       Date:  1980-09       Impact factor: 9.546

10.  Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.

Authors:  F Schlicht; C Staiger; J de Vries; U Gundert-Remy; R Hildebrandt; J Harenberg; N S Wang; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.